New groups are always welcome to join provided they can meet the minimum eligibility requirements.

Updated 03 April, 2024

OTTA Site Study Name Contact Email OCAC
AOC Australian Ovarian Cancer Study (AOCS) David Bowtell david.bowtell@petermac.org AUS
AOV OVarian Types study Linda Kelemen lkelemen@post.harvard.edu AOV
BAR BARTS Ranjit Manchanda r.manchanda@ucl.ac.uk
BAV Bavarian Ovarian Cancer Cases and Controls Peter Fasching Peter.Fasching@uk-erlangen.de BAV
BEL Belgian Ovarian Cancer Study (BCOS) Toon Van Gorp toon.vangorp@uzleuven.be
BGS Breakthrough Generations Study Anthony Swerdlow Anthony.Swerdlow@icr.ac.uk BGS
BOB Basel Ovarian Biobank Viola Heinzelmann-Schwarz viola.heinzelmann@usb.ch
BRO BRITROC Iain Mcneish i.mcneish@imperial.ac.uk
BRZ Brazil Gynecologic Tumor Bank (BRZ) study Francisco Candido dos Reisfjcreis@fmrp.usp.br BRZ
CAL Calgary HGSC chemoresistant Martin Kobel Martin.Koebel@albertapubliclabs.ca
CAM Cambridge Ovarian Cancer Study James Brenton James.Brenton@cruk.cam.ac.uk
CNI Spanish National Cancer Centre (CNIO) study Javier Benitez jbenitez@cnio.es CNI
COE HJF /INOVA (Larry) George Maxwell George.Maxwell@inova.org COE
COH City of Hope - Omics and Ovarian Cancer Susan Neuhausen sneuhausen@coh.org
DER Derbyshire Heidi Sowter
DOV Diseases of the Ovary and their Evaluation Study Jennifer A. Doherty Jen.Doherty@hci.utah.edu DOV
DUK DUKE Andrew Berchuck andrew.berchuck@duke.edu DKE
GER German Ovarian Cancer Study Renée Turzanski Fortner r.fortner@dkfz.de GER
HAM Hamburg Barbara Schmalfeldt b.schmalfeldt@uke.de
HAW Hawaii Ovarian Cancer Study Marc Goodman marc.goodman@cshs.org HAW
HMC (HM-Ciocc) HM Hospitales – Centro Integral Oncológico HM Clara Campa Aranzazu Barquin Garcia abarquin@hmhospitales.com
HOC Helsinki Ovarian Cancer Study Ralf Butzow Ralf.Butzow@hus.fi HOC
HOP Hormones and Ovarian Cancer Prediction Kirsten Moysich kirsten.moysich@roswellpark.org HOP
HSA HSA biobank Nicki Meagher nicola.meagher@sydney.edu.au
JGO Japanese Gynecologic Oncology Study Akira Hirasawa hir-aki45@umin.org
KEM DNA-specimen in gynecologic oncologic malignancies Florian Heitz florian.heitz@gmx.net
KMC Kansas Medical Center Dineo Khabele khabeled@wustl.edu
KRA Korean Epithelial oVarian cancEr study (KoEVE) Sue K. Park suepark@snu.ac.kr KRA
LAX Women’s Cancer Research Institute (Cedars-Sinai Medical Center) Lester, Jenny JLester@mednet.ucla.edu LAX
LUO Lund University Cancer Center Ingrid Hedenfalk Ingrid.Hedenfalk@med.lu.se
MAY Mayo Clinic Ovarian Cancer Case Control Study Ellen Goode egoode@mayo.edu MAY+MAC
MSK Memorial Sloan Kettering Cancer Center Gynecology Tissue Bank Doug Levine MSK
MSS Mount Sinai School of Medicine John Martignetti John.Martignetti@mssm.edu
MUH Munich University Hospital Holger Bronger holger.bronger@tum.de
NCO North Carolina Ovarian Cancer Study Joellen Schildkraut jmschil@emory.edu NCO
NCT Natl. Centre of Tumor Diseases and the Dept. of Pathology, Heidelberg. Peter Sinn Peter.Sinn@med.uni-heidelberg.de
NEC New England Case-Control Study Kathryn Terry kterry@bwh.harvard.edu NEC
NEW University of Newcastle upon Tyne Richard Edmonson
NHS Nurses' Health Study Shelley Tworoger nhsst@channing.harvard.edu NHS
NOR Gynecologic Cancer Tissue Biobank, University of Bergen (NOR) study Line Bjorge line.bjorge@uib.no NOR
NOT Nottingham - Evaluating morphology and proteins expression in ovarian neoplasms Stewart Martin stewart.martin@nottingham.ac.uk
NTH CFMPB_297 The Netherlands Cancer Institute Hugo Horlings h.horlings@nki.nl
NUS Singapore Ruby Huang Yun Ju rubyhuang@ntu.edu.tw
ORE OREgon Tanja Pejovic pejovict@ohsu.edu ORE
PEN Penn BioTrust Ronny Drapkin rdrapkin@pennmedicine.upenn.edu
POC Poland Ovarian Cancer Study Jacek Gronwald jgron@pum.edu.pl POC
POL NCI Ovarian Case-Control Study in Poland Nico Wentzensen wentzenn@mail.nih.gov POL
PRM ProMark (PRM) study Francesmary Modugno modugnof@mwri.magee.edu
PVD Pelvic Mass Study Estrid Hogdall estrid.hoegdall@regionh.dk PVD
RPX Roswell Park Cancer Institute Case Series Kirsten Moysich Moysich@RoswellPark.org RPC
SEA UK Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) Ovarian Cancer StudyPaul Pharoah Paul.Pharoah@cshs.org SEA
SOC Southampton Ovarian Cancer Campbell Ian ian.campbell@petermac.org SOC
SRO Scottish Randomised Trial in Ovarian Cancer Iain McNeish i.mcneish@imperial.ac.uk SRO
STA Genetic Epidemiology of Ovarian Cancer Weiva Sieh weiva.sieh@mssm.edu STA
SWE Sweden Karin Sundfeldt karin.sundfeldt@obgyn.gu.se SWE
TBO Tampa Bay Ovarian Cancer Study Rebecca Sutphen Rebecca.Sutphen@epi.usf.edu TBO
TOC Toronto Ovarian Cancer Blaise Clarke Dr.Blaise.Clarke@uhn.ca
TRI University of California, Los Angeles Gottfried Konecny GKonecny@mednet.ucla.edu
TRT TORONTO Patricia Shaw Patricia.Shaw@uhn.ca
TUE Tuebingen University Women's Hospital (TUE) study Andreas Hartkopf andreas.hartkopf@med.uni-tuebingen.deTWH
TVA OVAL-Alberta Linda Cook LCook@salud.unm.edu OVA
TVB OVAL-BC Nhu Le nle@bccrc.ca
UCI UC Irvine Ovarian Cancer Study Hoda Anton-Culver hantoncu@uci.edu UCI
UKO UK Ovarian Cancer Population Study Susan Ramus s.ramus@unsw.edu.au UKO
ULA UCLA Gottfried Konecny GKonecny@mednet.ucla.edu
USC Univesity of Southern California Anna Wu Anna.Wu@med.usc.edu USC
VAN British Columbia Cancer Agency David Huntsman dhuntsma@bccancer.bc.ca VAN
VBL Vanderbilt Alicia Beeghly-Fadiel alicia.beeghly@Vanderbilt.Edu
WAG Perth Paul Cohen paul.cohen@uwa.edu.au
WMH WestMead Hospital Anna DeFazio anna.defazio@sydney.edu.au WMH
WOC Warsaw Ovarian Cancer Jolanta Kupryjanczyk jkupry@coi.waw.pl WOC
WUG Washington University Gynecologic Oncology Tissue Bank Maggie Mullen marymullen@wustl.edu